EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial

Henning Schäffler, Manuel Hörner, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W Beckmann und 5 weitere

Supportive Care in Cancer · 2026-12 · 34 (12)

DOI: 10.1007/s00520-026-11437-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 13.11.2026. Verfasst von Henning Schäffler und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Eating, Nausea. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Erlangen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Chemotherapy-induced nausea and vomiting (CINV) remains a challenging side effect, significantly impacting patients' quality of life [1–3]. Knowledge of eating behaviour’s influence on CINV is still limited. This study improves the understanding of CINV by investigating the impact of pre-chemotherapy food intake within the randomized Phase III SUCCESS C trial.

Methods

The SUCCESS C trial (NCT00847444), enrolled ,463 women with early-stage, HER2-negative breast cancer, receiving either three cycles of 5-fluorouracil (500 mg/m 2 ), epirubicin (100 mg/m 2 ), and cyclophosphamide (500 mg/m 2 ) followed by three cycles of docetaxel (100 mg/m 2 ) every 3 weeks (FEC), or six cycles of docetaxel (75 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) (TC). The present analysis included patients with completed CINV diary with hourly documentation over 5 days post-chemotherapy.

Results

CINV diary data during chemotherapy cycles 1–3 were available for 1582 patients, of whom 814 received FEC and 768 TC. Patient characteristics between chemotherapy arms were comparable. For FEC, pre-chemotherapy eating behaviour had a significant impact on nausea-free survival (NFS) in cycle 1 ( p = 0.04) and on emesis-free survival (EFS) in cycle 2 ( p = 0.02). For TC, no effect on NFS, but a significant effect on EFS ( p = 0.04 in cycle 1; p < 0.01 in cycle 2), was observed. Median EFS was approximately 120 h for all cycles and treatments.

Conclusion

This analysis demonstrates in both regimens less emesis, and for FEC less nausea, of patients with pre-chemotherapy food intake. The effect was most pronounced during the first 24 h after chemotherapy administration. Thus, eating behaviour influences CINV outcomes and warrants further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsEatingNauseaVomitingAdultAgedFemaleHumansMiddle AgedCyclophosphamideDocetaxelEpirubicinFluorouracilQuality of LifeTaxoids

Stichwörter der Autor:innen

Breast cancerCINVChemotherapyChemotherapy-induced nausea and vomitingEating behaviourEmesisFECRandomized trialTC

Substanzen

CyclophosphamideDocetaxelEpirubicinFluorouracilTaxoids

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
  • Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Biostatistics Unit, Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen, Germany.
  • Department of Women's Health, Tuebingen University, Tuebingen, Germany.
  • Department of Gynecology and Obstetrics, Klinikum St. Georg, Leipzig, Germany.
  • Schwerpunktpraxis Der Gynäkologie Und Onkologie Fürstenwalde, Klinikum Offenbach, Fürstenwalde, Spree, Germany.

Förderung

  • Universitätsklinikum Erlangen

Zitieren

APA

Schäffler, H., Hörner, M., Häberle, L., Goossens, C., Pfister, K., Leinert, E., Veselinovic, K., Brucker, S. Y., Köhler, U., Heinrich, G., Schneeweiss, A., Beckmann, M. W., Fasching, P. A., Janni, W. W., Rack, B., Heublein, S., & Ziegler, P. (2026). Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial. Supportive Care in Cancer, 34(12). https://doi.org/10.1007/s00520-026-11437-9

Vancouver

Schäffler H, Hörner M, Häberle L, Goossens C, Pfister K, Leinert E, et al. Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial. Supportive Care in Cancer. 2026;34(12). doi:10.1007/s00520-026-11437-9

BibTeX
@article{Schffler2026,
  author = {Schäffler, Henning and Hörner, Manuel and Häberle, Lothar and Goossens, Chloë and Pfister, Kerstin and Leinert, Elena and Veselinovic, Kristina and Brucker, Sara Y and Köhler, Uwe and Heinrich, Georg and Schneeweiss, Andreas and Beckmann, Matthias W and Fasching, Peter A and Janni, Wolfgang W and Rack, Brigitte and Heublein, Sabine and Ziegler, Philipp},
  title = {Impact of pre-chemotherapy food intake on chemotherapy-induced nausea and vomiting in patients with early breast cancer: a subanalysis of the randomized SUCCESS C trial},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {12},
  doi = {10.1007/s00520-026-11437-9}
}
Kostenlos starten →